Regeneron Shares Rise on Sustained Pasatru Efficacy in Longer-Term FOP Trial
Positive 84-week OPTIMA data for Pasatru lifted Regeneron shares, confirming sustained reduction in new heterotopic ossification and flare-ups.
Already have an account? Sign in.